What is claimed is:

1. A method of preparation of trientine tetrahydrochloride crystals, comprising:

step 1: adding an anti-solvent at a feeding temperature into a trientine tetrahydrochloride solution and stirring for crystallization;

wherein the feeding temperature ranges from 50℃ to 75℃ and the anti-solvent is an alcohol solvent;

wherein the stirring is made for a duration of at least one hour at a temperature ranging from 5℃ to 25℃.

2. The method of preparation as claimed in claim 1, wherein the anti-solvent is methanol.

3. The method of preparation as claimed in claim 2, wherein the step 1 further comprises drying crystals for LOD (loss on drying) of crystals <1%.

4. The method of preparation as claimed in claim 1, wherein the step 1 further comprises:

pre-step 1: preparing a reaction fluid by mixing a trientine dihydrochloride (TETA·2HCl) solution and an acidic solution for acidification; and

pre-step 2: adding an alcohol anti-solvent to the reaction fluid and stirring the reaction fluid for crystallization of crude trientine tetrahydrochloride.

5. The method of preparation as claimed in claim 4, wherein the reaction fluid has a pH value ≤ 2.0.

6. The method of preparation as claimed in claim 4, wherein the alcohol anti-solvent in the pre-step 2 is methanol.

7. The method of preparation as claimed in claim 4, wherein the stirring in the pre-step 2 is made for a duration of at least two hours at a temperature ranging from 15℃ to 35℃.

8. The method of preparation as claimed in claim 4, wherein the pre-step 2 further comprises drying the crude trientine tetrahydrochloride such that LOD (loss on drying) of the crude trientine tetrahydrochloride is <10%.

9. Trientine tetrahydrochloride, wherein the trientine tetrahydrochloride crystals feature XRPD peaks detected at 18.5, 21.9, 24.8, 25.2, 28.0, 31.5 and 35.6±0.1° 2θ.

10. A pharmaceutical composition, comprising the trientine tetrahydrochloride crystals prepared by the method of preparation as claimed in claims 1 to 8 or trientine tetrahydrochloride as claimed in claim 9.

11. The pharmaceutical composition as claimed in claim 10, wherein the pharmaceutical composition further comprises a vehicle pharmaceutically acceptable.

12. The pharmaceutical composition as claimed in claim 11, wherein the vehicle comprises a dissolving agent, a diluent, a lubricant, a binding agent, a depolymerizing agent, an effervescent mixture, a dye, a sweetening agent, a wetting agent, or a nontoxic and pharmaceutically inactive substance for pharmaceutical concoction.

13. The pharmaceutical composition as claimed in claim 10, wherein the formulation of the pharmaceutical composition may be a solution, an emulsion, a suspension, powders, a tablet, a pill, a troche or a capsule.

14. Use of trientine tetrahydrochloride crystals prepared by the method of preparation as claimed in claims 1 to 8 or trientine tetrahydrochloride as claimed in claim 9 for preparation of the pharmaceutical composition with which the Wilson’s disease is prevented or treated.